Physician profile
Michael Hall
NPI 1811941644
$7,642.99
in general payments reported to CMS, 2019-2025
15 companies · $4,495 in 2025
The $4,495 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2022: $2,463 · 2024: $550 · 2025: $4,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,425 · Food and Beverage: $805 · Travel and Lodging: $630 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,425.00 |
| Food and Beverage | $804.62 |
| Travel and Lodging | $629.76 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $185.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,055.43 | 2025 | Zynyz, Zynyz, Opzelura |
| Eisai INC. | $2,404.02 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $452.59 | 2019-2024 | |
| Beone Medicines USA, INC. | $181.37 | 2025 | Tevimbra |
| Regeneron Healthcare Solutions, INC. | $171.72 | 2024 | Libtayo |
| Genentech USA, INC. | $92.18 | 2025 | |
| Promega Corporation | $58.72 | 2022 | |
| Caris Mpi, INC. | $51.28 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $44.78 | 2024 | Myrisk |
| Daiichi Sankyo INC. | $43.93 | 2025 | |
| Gilead Sciences, INC. | $37.77 | 2025 | |
| Kerecis Limited | $30.65 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Merck Sharp & Dohme LLC | $18.55 | 2025 | Keytruda |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.